Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced the granting of restricted stock units (RSUs) to 42 new employees under its Inducement Equity Plan. The Compensation Committee of Xeris' Board of Directors approved the grant on October 1, 2024, for an aggregate of 364,000 shares of common stock.
These RSUs are designed as an inducement for new hires, in compliance with NASDAQ Listing Rule 5635(c)(4). The grants will vest over three years in equal annual installments, contingent on continued employment with Xeris or its subsidiaries. All awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and relevant award agreements.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) ha annunciato l'assegnazione di unità azionarie vincolate (RSU) a 42 nuovi dipendenti nell'ambito del suo Piano di Induzione di Capitale. Il Comitato Remunerazioni del Consiglio di Amministrazione di Xeris ha approvato l'assegnazione il 1 ottobre 2024, per un totale di 364.000 azioni di capitale ordinario.
Queste RSU sono progettate come incentivo per le nuove assunzioni, in conformità con la Regola di quotazione NASDAQ 5635(c)(4). Le concessioni matureranno nel corso di tre anni in rate annuali uguali, subordinate al proseguimento dell'impiego presso Xeris o le sue sussidiarie. Tutti i premi sono soggetti ai termini e alle condizioni del Piano di Induzione di Capitale di Xeris e ai relativi accordi di assegnazione.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) ha anunciado la concesión de unidades de acciones restringidas (RSU) a 42 nuevos empleados bajo su Plan de Capital de Inducción. El Comité de Compensación de la Junta de Directores de Xeris aprobó la concesión el 1 de octubre de 2024, por un total de 364,000 acciones de acciones ordinarias.
Estas RSU están diseñadas como un incentivo para las nuevas contrataciones, de acuerdo con la Regla de Cotización NASDAQ 5635(c)(4). Las concesiones se consolidarán durante tres años en cuotas anuales iguales, dependiendo de la permanencia en el empleo con Xeris o sus filiales. Todos los premios están sujetos a los términos y condiciones del Plan de Capital de Inducción de Xeris y a los acuerdos de concesión relevantes.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS)는 인센티브 주식 계획에 따라 42명의 신규 직원에게 제한 주식 단위(RSU)를 부여했다고 발표했습니다. Xeris의 보상위원회는 2024년 10월 1일에 총 364,000주의 보통주에 대한 부여를 승인했습니다.
이 RSU는 새로운 채용을 유도하기 위해 설계되었으며, NASDAQ 상장규칙 5635(c)(4) 준수합니다. 부여된 RSU는 3년 동안 동등한 연간 할부로 분할되며, Xeris 또는 그 자회사에서의 지속적인 고용을 조건으로 합니다. 모든 상은 Xeris의 유인 자본 계획의 조건과 관련 계약의 조건에 따릅니다.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) a annoncé l'octroi d'unités d'actions restreintes (RSU) à 42 nouveaux employés dans le cadre de son Plan d'Équité d'Incitation. Le Comité de Rémunération du Conseil d'Administration de Xeris a approuvé l'octroi le 1er octobre 2024, pour un total de 364 000 actions ordinaires.
Ces RSU sont conçues comme une incitation pour les nouvelles recrues, conformément à la Règle de Cotation NASDAQ 5635(c)(4). Les octrois s'acquitteront sur trois ans en versements annuels égaux, conditionnés à un emploi continu chez Xeris ou ses filiales. Tous les prix sont soumis aux termes et conditions du Plan d'Équité d'Incitation de Xeris et aux accords d'attribution pertinents.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) hat die Gewährung von eingeschränkten Aktieneinheiten (RSUs) an 42 neue Mitarbeiter im Rahmen seines Anreizkapitalplans bekannt gegeben. Der Vergütungsausschuss des Vorstands von Xeris genehmigte die Gewährung am 1. Oktober 2024 für insgesamt 364.000 Aktien des Stammkapitals.
Diese RSUs sind als Anreiz für Neueinstellungen konzipiert und entsprechen den NASDAQ-Listing-Regeln 5635(c)(4). Die Gewährungen werden über drei Jahre verteilt in gleichen jährlichen Raten, abhängig von einer fortdauernden Anstellung bei Xeris oder seinen Tochtergesellschaften, fällig sein. Alle Auszeichnungen unterliegen den Bedingungen des Anreizkapitalplans von Xeris und den entsprechenden Auszeichnungsvereinbarungen.
- Xeris is expanding its workforce with 42 new employees
- The company is using equity incentives to attract and retain talent
- The issuance of new shares may lead to potential dilution for existing shareholders
Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a pipeline of development programs using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004364483/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
How many restricted stock units did Xeris Biopharma (XERS) grant on October 1, 2024?
How many new employees received restricted stock units from Xeris Biopharma (XERS)?
What is the vesting schedule for the restricted stock units granted by Xeris Biopharma (XERS)?
Under which plan did Xeris Biopharma (XERS) grant the restricted stock units?
